Literature DB >> 21147935

Reduction of immunogenicity of anthrax vaccines subjected to thermal stress, as measured by a toxin neutralization assay.

Juan Castelán-Vega1, Laura Corvette, Lev Sirota, Juan Arciniega.   

Abstract

We report that a toxin neutralization assay (TNA) can detect a decrease in the immunogenicity of anthrax vaccines as a consequence of brief exposure to elevated temperature. This attribute of TNA may help in adopting immunogenicity as a replacement of the current potency test, which involves protection from lethal challenge.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21147935      PMCID： PMC3067352          DOI： 10.1128/CVI.00267-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  10 in total

1.  Validation of assays for use with combination vaccines.

Authors:  J Klein; R Capen; R Mancinelli; R Robinett; P J Pietrobon; J Quinn; T Schofield
Journal:  Biologicals       Date:  1999-03       Impact factor: 1.856

2.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

4.  Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.

Authors:  Inge Berthold; Maria-Luz Pombo; Leslie Wagner; Juan L Arciniega
Journal:  Vaccine       Date:  2005-03-14       Impact factor: 3.641

5.  Thermostabilization of protective antigen--the binding component of anthrax lethal toxin.

Authors:  C Radha; P Salotra; R Bhat; R Bhatnagar
Journal:  J Biotechnol       Date:  1996-10-01       Impact factor: 3.307

6.  Anthrax vaccine powder formulations for nasal mucosal delivery.

Authors:  Ge Jiang; Sangeeta B Joshi; Laura J Peek; Duane T Brandau; Juan Huang; Matthew S Ferriter; Wendy D Woodley; Brandi M Ford; Kevin D Mar; John A Mikszta; C Robin Hwang; Robert Ulrich; Noel G Harvey; C Russell Middaugh; Vincent J Sullivan
Journal:  J Pharm Sci       Date:  2006-01       Impact factor: 3.534

7.  Thermal inactivation of protective antigen of Bacillus anthracis and its prevention by polyol osmolytes.

Authors:  Samer Singh; Aparna Singh; Mohd Azhar Aziz; Syed Mohsin Waheed; Rajiv Bhat; Rakesh Bhatnagar
Journal:  Biochem Biophys Res Commun       Date:  2004-09-24       Impact factor: 3.575

8.  Gln277 and Phe554 residues are involved in thermal inactivation of protective antigen of Bacillus anthracis.

Authors:  Samer Singh; Nidhi Ahuja; Vibha Chauhan; E Rajasekaran; Syed Mohsin Waheed; Rajiv Bhat; Rakesh Bhatnagar
Journal:  Biochem Biophys Res Commun       Date:  2002-09-06       Impact factor: 3.575

9.  Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.

Authors:  Han Li; Stephen D Soroka; Thomas H Taylor; Karen L Stamey; Kelly Wallace Stinson; Alison E Freeman; Darbi R Abramson; Rita Desai; Li X Cronin; J Wade Oxford; Joseph Caba; Cynthia Pleatman; Sonal Pathak; Daniel S Schmidt; Vera A Semenova; Sandra K Martin; Patricia P Wilkins; Conrad P Quinn
Journal:  J Immunol Methods       Date:  2008-02-08       Impact factor: 2.303

10.  Validation of the anthrax lethal toxin neutralization assay.

Authors:  Donna Hering; William Thompson; John Hewetson; Stephen Little; Sarah Norris; Judith Pace-Templeton
Journal:  Biologicals       Date:  2004-03       Impact factor: 1.856
  10 in total
  6 in total

1.  Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen.

Authors:  L K Petersen; Y Phanse; A E Ramer-Tait; M J Wannemuehler; B Narasimhan
Journal:  Mol Pharm       Date:  2012-03-20       Impact factor: 4.939

2.  Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine.

Authors:  Vidyashankara Iyer; Lei Hu; Carole E Schanté; David Vance; Chrystal Chadwick; Nishant Kumar Jain; Robert N Brey; Sangeeta B Joshi; David B Volkin; Kiran K Andra; James G Bann; Nicholas J Mantis; C Russell Middaugh
Journal:  Hum Vaccin Immunother       Date:  2013-08-07       Impact factor: 3.452

3.  Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.

Authors:  Hang Lu; Jason Catania; Katalin Baranji; Jie Feng; Mili Gu; Janet Lathey; Diane Sweeny; Hannah Sanford; Kavita Sapru; Terry Patamawenu; June-Home Chen; Alan Ng; Zenbework Fesseha; Stefanie Kluepfel-Stahl; Jacob Minang; David Alleva
Journal:  Clin Vaccine Immunol       Date:  2013-05-01

4.  Quantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R.

Authors:  Xiaodong Zai; Jun Zhang; Ju Liu; Jie Liu; Liangliang Li; Ying Yin; Ling Fu; Junjie Xu; Wei Chen
Journal:  Toxins (Basel)       Date:  2016-02-25       Impact factor: 4.546

5.  Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.

Authors:  Jennifer G Wright; Brian D Plikaytis; Charles E Rose; Scott D Parker; Janiine Babcock; Wendy Keitel; Hana El Sahly; Gregory A Poland; Robert M Jacobson; Harry L Keyserling; Vera A Semenova; Han Li; Jarad Schiffer; Hanan Dababneh; Sandra K Martin; Stacey W Martin; Nina Marano; Nancy E Messonnier; Conrad P Quinn
Journal:  Vaccine       Date:  2013-12-25       Impact factor: 4.169

6.  Binding of the von Willebrand Factor A Domain of Capillary Morphogenesis Protein 2 to Anthrax Protective Antigen Vaccine Reduces Immunogenicity in Mice.

Authors:  Fabiana Freire Mendes de Oliveira; Sireesha Mamillapalli; Srinivas Gonti; Robert N Brey; Han Li; Jarad Schiffer; Arturo Casadevall; James G Bann
Journal:  mSphere       Date:  2020-01-15       Impact factor: 4.389
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.